Insider Buying: Trevena Inc (TRVN) CEO Purchases 50,000 Shares of Stock

Trevena Inc (NASDAQ:TRVN) CEO Maxine Gowen purchased 50,000 shares of the business’s stock in a transaction dated Friday, February 1st. The stock was bought at an average cost of $1.02 per share, for a total transaction of $51,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

TRVN stock opened at $1.41 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.30 and a current ratio of 4.30. The firm has a market capitalization of $111.14 million, a PE ratio of -1.17 and a beta of 2.62. Trevena Inc has a twelve month low of $0.38 and a twelve month high of $3.58.

Get Trevena alerts:

Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.07. The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.00 million. On average, analysts expect that Trevena Inc will post -0.37 earnings per share for the current fiscal year.

A number of research analysts have recently weighed in on the company. Zacks Investment Research raised Trevena from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Thursday. HC Wainwright downgraded Trevena from a “buy” rating to a “neutral” rating and cut their price target for the company from $3.00 to $0.75 in a research note on Monday, November 5th. Needham & Company LLC downgraded Trevena from a “buy” rating to a “hold” rating in a research note on Friday, October 12th. Finally, JMP Securities increased their price target on Trevena from $4.00 to $15.00 and gave the company an “outperform” rating in a research note on Friday, October 12th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $5.54.

A number of institutional investors have recently modified their holdings of TRVN. BlackRock Inc. raised its stake in Trevena by 151.4% during the 3rd quarter. BlackRock Inc. now owns 1,873,311 shares of the biopharmaceutical company’s stock worth $3,971,000 after buying an additional 1,128,041 shares during the period. FMR LLC raised its stake in Trevena by 24.0% during the 2nd quarter. FMR LLC now owns 5,288,100 shares of the biopharmaceutical company’s stock worth $7,615,000 after buying an additional 1,022,830 shares during the period. Vanguard Group Inc raised its stake in Trevena by 29.2% during the 3rd quarter. Vanguard Group Inc now owns 2,618,634 shares of the biopharmaceutical company’s stock worth $5,552,000 after buying an additional 592,152 shares during the period. Vanguard Group Inc. raised its stake in Trevena by 29.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,618,634 shares of the biopharmaceutical company’s stock worth $5,552,000 after buying an additional 592,152 shares during the period. Finally, Millennium Management LLC raised its stake in Trevena by 112.3% during the 2nd quarter. Millennium Management LLC now owns 1,005,820 shares of the biopharmaceutical company’s stock worth $1,448,000 after buying an additional 532,129 shares during the period. 37.96% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Insider Buying: Trevena Inc (TRVN) CEO Purchases 50,000 Shares of Stock” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/4136441/insider-buying-trevena-inc-trvn-ceo-purchases-50000-shares-of-stock.html.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

See Also: Price to Earnings Ratio (PE) Basics